The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of compound Danshen dropping pills
(CDDP) in improving ventricular remodeling and cardiac function after acute anterior wall
ST-Elevation myocardial infarction(STEMI). 268 patients with acute anterior wall STEMI after
primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to CDDP
group(n=134) and control group(n=134) with follow-up of 24 weeks. Both groups are treated
with standard therapy of STEMI, with the CDDP group administrating 20 tablets of CDDP before
pPCI and 10 tablets three times a day after pPCI and the control group treated with placebo
at the same time. The primary endpoint is 24-week echocardiographic including left ventricle
ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left
ventricular end-systolic volume index (LVESVI).The secondary endpoint is the change in N
terminal pro-B-type natriuretic peptide（NT-proBNP ）level, arrhythmia and cardiovascular
events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart
failure or angina pectoris).
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University